Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be ...

PATHWAY HER2 (4B5) test standardizes IHC processes, reducing variability and ensuring reliable results, enhancing clinical decision-making. Roche aims to solidify leadership in HER2 diagnostics ...

HER2 interpretation in breast cancer is evolving. With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in HER2 diagnostics, helping to expand patient ...

The IHC staining was performed for subtyping, ER, PR, HER2, and Ki-67 proliferation markers ... EB contributed to study design, sample and data acquisition, analysis, interpretation, and writing of ...

Rabbit Monoclonal Primary Antibody Package Insert [4] NORDIQC HER2 IHC Assessment Run B37 2024 [5] Mayr D, et al. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression ...

Basel, 31 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

HER2 interpretation in breast cancer is evolving. With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in HER2 diagnostics, helping to expand patient access ...